Le Lézard
Classified in: Transportation, Business, Covid-19 virus
Subjects: CCA, SHM

China Automotive Systems Announces Annual Meeting on August 26, 2022


CAAS announces the conference call and webcast information for the Annual Meeting of Stockholders to be held on Friday, August 26, 2022 at 9:00 AM local time, or 9:00 PM EDT on August 25, 2022 

WUHAN, China, Aug. 18, 2022 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced the Annual Meeting of Stockholders of China Automotive Systems, Inc. will be held on Friday, August 26, 2022 at 9:00 AM local time at the Second Floor Meeting Room, D8 Henglong Building, Optics Valley Software Park, No. 1 Guanshan First Avenue, Wuhan City, Hubei Province, the People's Republic of China. The Company has also set up a conference room on August 25, 2022 at 9:00 PM at Henglong USA Corporation, 2546 Elliott Drive, Troy, Michigan, U.S., for the Company's shareholders to participate via a WebEx connection.

Shareholders may access the annual meeting by dialing U.S./Canada +1-408-792-6300, pin number 2632 965 7608, and ask for the China Automotive Systems AGM conference call.

A live webcast of the conference call will be available at: https://caas-usa.webex.com/caas-usa/j.php?MTID=m93d47af4c7da5c6291044a30454ca9b9

Meeting number (access code): 2632 965 7608

Meeting password: GHzJcrH37F3

About China Automotive Systems, Inc.

Based in Hubei Province, the People's Republic of China, China Automotive Systems, Inc. is a leading supplier of power steering components and systems to the Chinese automotive industry, operating through ten Sino-foreign joint ventures. The Company offers a full range of steering system parts for passenger automobiles and commercial vehicles. The Company currently offers four separate series of power steering with an annual production capacity of over 6 million sets of steering gears, columns and steering hoses. Its customer base is comprised of leading auto manufacturers, such as China FAW Group, Corp., Dongfeng Auto Group Co., Ltd., BYD Auto Company Limited, Beiqi Foton Motor Co., Ltd. and Chery Automobile Co., Ltd. in China, and Fiat Chrysler Automobiles (FCA) and Ford Motor Company in North America. For more information, please visit: http://www.caasauto.com.

Forward-Looking Statements

This press release contains statements that are "forward-looking statements" as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. These forward-looking statements include statements regarding the qualitative and quantitative effects of the accounting errors, the periods involved, the nature of the Company's review and any anticipated conclusions of the Company or its management and other statements that are not historical facts. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. As a result, the Company's actual results could differ materially from those contained in these forward-looking statements due to a number of factors, including those described under the heading "Risk Factors" in the Company's Form 10-K annual report filed with the Securities and Exchange Commission on March 30, 2022, and in documents subsequently filed by the Company from time to time with the Securities and Exchange Commission. If the outbreak of COVID-19 is not effectively and timely controlled, our business operations and financial condition may be materially and adversely affected as a result of the deteriorating market outlook for automobile sales, the slowdown in regional and national economic growth, weakened liquidity and financial condition of our customers or other factors that we cannot foresee. Any of these factors and other factors beyond our control, could have an adverse effect on the overall business environment, cause uncertainties in the regions where we conduct business, cause our business to suffer in ways that we cannot predict and materially and adversely impact our business, financial condition and results of operations. A prolonged disruption or any further unforeseen delay in our operations of the manufacturing, delivery and assembly process within any of our production facilities could continue to result in delays in the shipment of products to our customers, increased costs and reduced revenue.  We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.

For further information, please contact:

Jie Li
Chief Financial Officer
China Automotive Systems, Inc.
Email: [email protected]

Kevin Theiss
Investor Relations
Tel: +1-212-510-8922
Email: [email protected]

SOURCE China Automotive Systems, Inc.


These press releases may also interest you

at 06:30
Leica Biosystems is pleased to announce that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the US Food and Drug Administration. Previously sold into the clinical market under an enforcement discretion due...

at 03:05
Skechers, The Comfort Technology Company®, has opened its first concept store in Brussels on its most famous shopping street, Rue Neuve. Together with its store on Antwerp's Meir and planned Bruges concept store opening in mid-May, the Company is...

at 03:01
SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") is pleased to provide an update on its significant...

at 02:27
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...



News published on and distributed by: